German life sciences company Bayer (BAYN: DE) was trading 7% lower in mid-afternoon activity on Thursday after presenting its first-quarter 2023 financial results and latest outlook for 2023 as a whole.
The group described a slow start to the year, with sales 1.7% lower than they were in the first quarter of 2023, at 14.39 billion euros ($15.7 billion). Earnings before interest, taxes, depreciation and amortization during the quarter declined 14.9% to 4.47 billion euros, below the average analyst estimate of 4.63 billion euros in a consensus posted on Bayer’s website.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze